Mutation status of refractory to imatinib patients with chronic myeloid leukemia

• Main Authors: E. G. Ovsyannikova, K. D. Kaplanov, T. Yu. Klitochenko, A. V. Misyurin, I. L. Davydkin, L. V. Zaklyakova, E. A. Popov, B. N. Levitan
• Format: Article
• Language: Russian
• Published: ABV-press 2014-07-01
• Series: Onkogematologiâ
• Subjects: chronic myeloid leukemia; bcr-abl mutations; resistance; imatinib
• Online Access: https://oncohematology.abvpress.ru/ongm/article/view/72
• ISSN: 1818-8346

Mutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and secondary imatinib resistance was analyzed. BCR-ABL mutations identified by direct DNA sequencing. BCR-ABL kinase domain mutations were detected in 30.5 % (11 of 36) of those patients. Most of identified mutations were missense mutations: Q252H, M244V, G250E, Y253F/H, E255K/V, T315I, M351T, F359V, F359C, F486S. Patients with BCR-ABL mutations have significantly lower 4-year event-free survival compared with CML patients without mutations (18 % vs. 53 %; р = 0.003). The results can be used as reference information in deciding on therapy in imatinib resistant CML patients with clinically relevant BCR-ABL mutations.